Loading the session
Loading the session
Loading instrument
$14.09
+0.43%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:59 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −3.1% (SPY −1.6%). 3 months: +5.8% (SPY −0.4%). 1 year: +262.5% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: DRTS, SPY · as of 4 Nov 2026
3.4M shares were sold short at the 15 Oct 2026 settlement, 3.8% of the 90.3M shares outstanding; covering them would take 8.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Closed at $14.03 on 4 Nov 2026: 11.1% below the 52-week high of $15.79 (17 Sep 2026) and 309.0% above the low of $3.43 (21 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $14.03 was 1.1% below its 50-day average ($14.18) and 31.2% above its 200-day average ($10.69). It has closed above the 200-day for 377 sessions, since 7 May 2025. The 50-day average crossed above the 200-day on 6 Jun 2025, 355 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
July 5, 2022
+38.71%June 10, 2022
+40.20%March 24, 2022
+26.49%